Ivemend

Fosaprepitant, the active ingredient in Ivemend, is a NK1 receptor antagonist presented as a 150 mg/100 mL injectable solution for intravenous use. It prevents chemotherapy‑induced nausea and vomiting in adult patients receiving highly or moderately emetogenic chemotherapy, addressing both acute and delayed phases of emesis. GNH USA supplies Ivemend as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Fosaprepitant, an NK1 receptor antagonist, is indicated for the prevention of chemotherapy‑induced nausea and vomiting (CINV).

- Chemotherapy‑induced nausea and vomiting: Reduces both acute and delayed nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy. - Combination antiemetic therapy: Used together with a 5‑HT3 antagonist and dexamethasone to enhance overall antiemetic control. - Adult oncology patients: Provides prophylaxis against CINV in adult patients undergoing cancer treatment.

Fosaprepitant is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain or erythema - Fatigue or asthenia - Constipation or diarrhea - Headache

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction - Severe infusion‑related reaction (e.g., bronchospasm) - Cardiac arrhythmia or QT‑interval prolongation - Severe hypotension or cardiovascular collapse

When using Ivemend, consider the following precautions.

- Pregnancy: Category B; use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: Caution advised; limited data are available, and a decision should be based on clinical judgment. - Renal impairment: No dose adjustment is required, but monitor renal function in severe cases. - Hepatic impairment: Use with caution in patients with severe hepatic disease; monitor liver enzymes. - Drug interactions: Review concomitant medications, especially CYP3A4 modulators and other NK1 antagonists. - Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Fosaprepitant may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce fosaprepitant exposure. - Concomitant use with other NK1 antagonists: increased risk of additive toxicity. - QT‑prolonging agents (e.g., certain antiarrhythmics): may heighten the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may increase fosaprepitant plasma levels. - Warfarin: monitor INR as fosaprepitant can affect its metabolism. - Dexamethasone: dose adjustment may be needed because fosaprepitant can alter its clearance.